Markets Brief: What to Watch for in Q3 Earnings
Albertsons, Walgreens, and Moderna rally. Software companies fall on expectations of more rate hikes.
Albertsons, Walgreens, and Moderna rally. Software companies fall on expectations of more rate hikes.
Companies have only just begun to report third-quarter results, but investors are braced for the worst. Punk earnings could spell more downside for an already beaten-up stock market.
“We’re expecting earnings to be poor,” says Phil Orlando, chief equity market strategist at Federated Hermes. “The trends we were seeing earlier in the year have continued into the third quarter and the fourth quarter and that will lead to decelerating growth and rapidly deteriorating profit margins.”
One exception: Energy companies will likely power ahead and continue to post stronger-than-expected profits as demand for oil and natural gas is strong and prices remain elevated. It was the only sector to see meaningful upward revisions to earnings in the quarter. Another bright spot: Revenue across the board should remain in positive territory, benefiting from higher inflation.
“The swing factor is guidance,” says Orlando, referring to the practice of senior executives providing estimates for the coming quarter and year, and setting expectations surrounding their businesses. “I think it will be very cautious. Forward guidance for the fourth quarter and full year 2023 will be challenged.”
Bank of America’s equity and quantitative strategist Savita Subramanian in a third-quarter preview called “Buckle Up!” says she expects earnings to slightly miss estimates but sees big downside risk starting in the fourth quarter. “Guidance is going to be terrible,” she says. She’ll be listening for mentions of recession, weak demand, and layoffs.
“Pricing is peaking, demand is slowing, yet costs are sticky,” says Subramanian. “Our Corporate Misery Indicator further declined in 3Q, indicating worsening misery and pointing to increased margin pressure. Demand is key, which was the main driver of pricing power post-COVID. Weakening demand points to weaker pricing and margin pressure. Bloated inventories also pose downside risk to margins, particularly for many retailers.”
In a recent piece titled “The End of Earnings Growth,” Jeff Kleintop, chief global investment strategist at Charles Schwab, says stock valuations will come under further pressure as third-quarter earnings will likely fall short of expectations. While Wall Street analysts have been lowering their estimates steadily to reflect a slower growth environment, expectations are still too high, he says.
Kleintop notes the historically tight correlation between the global manufacturers Purchasing Managers’ Index and earnings growth at companies. Trends in the PMI tend to be a forward indicator of future earnings.
“Leading components of the PMI, such as new orders, suggest a further economic slowdown in the months ahead and a coming decline in earnings,” Kleintop wrote in his report. “If so, the erosion of earnings as a key support for stocks could lead to a further stock market sell-off in the weeks ahead as corporate leaders guide analysts to further lower their earnings estimates.”
Corporate earnings held up well in the first half despite the headwinds of inflation and supply chain disruptions. Now, a double-trouble combination of slowing economic growth and eroding profit margins is beginning to hurt.
Higher costs for wages, transportation and shipping, warehousing, and fuel and energy are cutting into companies’ profits and margins. Penny-pinching consumers are pulling back and trading down, squeezed by sky-high prices for rent, food, medical care, new vehicles, and mass transit, including airfares.
Indeed, the latest inflation data for September released last week showed prices climbing a higher-than-expected 8.2% from a year earlier. The so-called core Consumer Price Index, which excludes food and energy prices, rose to a new peak of 6.6%.
Persistent high inflation will keep pressure on the Federal Reserve to continue boosting the federal-funds rate as it attempts to rein in the fastest pace of growth in consumer prices in 40 years.
Technology and consumer discretionary companies will be the most challenged in this environment, according to Orlando of Federated Hermes. With consumer spending such an important factor in U.S. economic growth—representing about 70% of gross domestic product—the holiday season bears close watching. He’s concerned margins could be under an extraordinary amount of pressure. One cautionary sign: Walmart (WMT) plans to hire far fewer seasonal workers during the holiday season than it did last year. It will also offer current employees extra hours before adding to staff.
Depending on the guidance companies give, and based on a forecast for negative economic growth in the first and second quarters and full-year 2023, Federated Hermes is considering cutting its 2023 earnings estimate for the S&P 500 to $200 from $230. That compares with the current Wall Street consensus of $238.
Bank of America’s Subramanian is also forecasting earnings of $200 on the S&P in 2023.
“We’re on a glide path to an outright recession next year,” says Orlando. “Directionally, that’s what we’re thinking.”
Albertsons’ (ACI) stock surged after Kroger (KR) agreed to purchase the supermarket operator in a $24.6 billion deal, CNBC reported. Shares of Kroger inched up.
“While we believe a combination between the two largest pure-play grocers in the United States would create scale benefits (and associated cost and purchasing leverage) that would help fend off burgeoning omnichannel titans Walmart and Amazon, we suspect overlap between the two chains’ footprints in many markets may lead regulators to scrutinize a transaction closely,” says Zain Akbari, Morningstar equity analyst.
Walgreens Boots Alliance (WBA) stock rallied after the pharmacy retailer posted results that beat market expectations. Management now expects an earnings per share range of $4.45-$4.65 for fiscal 2023.
“This guidance is driven by rapid acceleration of its U.S. healthcare business and core business growth compensating for adverse currency movements and COVID-19 vaccine volume headwinds,” Morningstar senior equity analyst Julie Utterback says.
Shares of Moderna (MRNA) and Merck (MRK) were up on news the two drug manufacturers would team up to produce a personalized cancer vaccine for patients with high-risk melanoma, CNBC reported.
Five9 (FIVN) shares plunged after chief executive Rowan Trollope said he would resign from the software company, CNBC reported.
Volatility in solar stocks continued with the likes of SunPower (SPWR) and Sunrun (RUN) closing the week lower, after a hotter-than-expected CPI report was seen as further indication that the Federal Reserve would continue aggressively hiking interest rates, raising concerns for the high-growth industry.
Tech stocks also fell during the week on increased concerns about a possible recession, with Zscaler (ZS), RingCentral (RNG), and Atlassian (TEAM) among the worst performers.
Sandy Ward does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.